News on immunohistochemistry and other tissue-based testing methods.
The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for patients who had not been in remission for five years and who had not been taking tamoxifen.
Providers are looking to innovation in products and pricing to convince pathologists unsure of the value in switching to digital solutions.
The firm is using $350,000 in recently awarded NIH funds for a clinical study of its glycan test for predicting response to chemotherapy in ovarian cancer.
The firm's algorithm rapidly identifies skin irregularities by comparing the image to data from its cloud-based database, acting as a diagnostic aid for pathologists.
The firm recently announced a $3.15 million grant from the NIH, and it supported work that resulted in the first-ever digital primary diagnosis of a suspected cancer case.
